Request Appointment
353 East 68th StreetNew York, NY 10065
Overview of Dr. Morris
Dr. Michael Morris is an oncologist in New York, NY and is affiliated with Memorial Sloan-Kettering Cancer Center. He received his medical degree from Icahn School of Medicine at Mount Sinai and has been in practice 23 years. He specializes in genitourinary oncology and his clinical and research focus is on high risk, recurrent, and metastatic prostate cancer, regarding drug, imaging, and biomarker development.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1997 - 2000
New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 1994 - 1997
Icahn School of Medicine at Mount SinaiClass of 1994
Certifications & Licensure
FL State Medical License 2021 - Present
NJ State Medical License 2019 - 2027
NY State Medical License 1996 - 2027
NH State Medical License 2024 - 2024
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Sunrise Ambulatory Care, Allscripts, 2016-2017
- CMS Meaningful Use Stage 1 Certification MyMSK, Memorial Sloan Kettering, 2016-2017
Clinical Trials
- Calcitriol and Zoledronate in Treating Patients With Progressive Prostate Cancer Start of enrollment: 1999 Oct 01
- Testosterone in Treating Patients With Progressive Prostate Cancer That No Longer Responds to Hormone Therapy Start of enrollment: 2000 Feb 01
- Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer Start of enrollment: 2001 Jun 01
Publications & Presentations
PubMed
- Correlative Biomarker Analysis of PSMA Expression on CTCs and PSMA Imaging in a Phase I Study of PSMA-Targeted Tubulysin Conjugate EC1169.Samir Zaidi, Phillip H Kuo, Tiago Paiva Prudente, Kristine P Lacuna, Hani M Babiker
Clinical Cancer Research. 2026-05-01 - 4 citationsTrial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4.Andrew J Armstrong, Michael J Morris, Wassim Abida, Rahul R Aggarwal, Emmanuel S Antonarakis
Journal of Clinical Oncology. 2026-05-01 - Prognostic Value of Interim PSMA-PET Total Tumor Volume for Overall Survival Within ENZA-p, A Randomized Phase 2 Trial of Enzalutamide Versus Enzalutamide Plus [Lu] Lu...Louise Emmett, Nathan Papa, Oliver Sartor, Michael J Morris, Shalini Subramaniam
European Urology. 2026-04-08
Press Mentions
Trump Suggested Biden Hid Cancer Diagnosis. Here's What We Know About the TimelineMay 22nd, 2025- Biden’s Diagnosis Puts Spotlight on Prostate Cancer ScreeningMay 20th, 2025
- How Doctors Treat Aggressive Prostate Cancer like Joe Biden’sMay 19th, 2025
Professional Memberships
- Member
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
Great West PPO
Humana ChoiceCare Network PPOMultiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
